Overview of the treatment of myelodysplastic syndromes - UpToDate
INTRODUCTION Myelodysplastic syndromes (MDS) comprise a group of hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias (ie, anemia, neutropenia, and/or thrombocytopenia), and abnormal cellular maturation. Patients are at risk for symptoms related to anemia, infection, and bleeding, and they have variable rates of transformation to acute myeloid leukemia (AML). (See "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)".) This topic will provide an overview of the treatment of MDS. Detailed discussions of the following issues are presented separately: ● (See "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)".) ● (See "Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults".) ● (See "Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS".) ● (See "Treatment of lower-risk myelodysplastic syndromes (MDS)".) ● (See "Treatment
UpToDate
Explore this link on the map →